Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout ...Middle East

Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo Pozdeutinurad was overall well tolerated, and the safety profile was consistent with previous studies STOCKHOLM, May 21, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today...

Hence then, the article about positive topline results from the pivotal phase 3 reduce 2 study of pozdeutinurad in gout was published today ( Thursday 21/05/2026 - 11:56 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout )

Also on site :

• UFO Files: 13 Fighter Jets Chased Flying Object, Star-Shaped Entity Seen
• Eli Lilly says next-generation weight loss drug clears crucial obesity trial
• Trump promised no-cost IVF treatment for all. That’s still a long way off